Top Page
Fusion Antibodies Plc
(LSE:FAB)
Fusion Antibodies Plc (FAB) vs. iShares MSCI United Kingdom ETF (EWC)
Fusion Antibodies Plc Business Overview & Revenue Model
Fusion Antibodies Plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.97M | 1.97M | 1.14M | 2.90M | 4.80M | 4.17M |
| Gross Profit | 430.00K | 430.00K | -265.00K | 202.00K | 1.72M | 1.31M |
| EBITDA | -1.62M | -1.62M | -2.06M | -2.48M | -573.00K | -532.00K |
| Net Income | -1.71M | -1.71M | -2.23M | -2.60M | -1.20M | -2.90M |
Balance Sheet | ||||||
| Total Assets | 1.32M | 1.32M | 2.42M | 2.06M | 4.92M | 5.83M |
| Cash, Cash Equivalents and Short-Term Investments | 359.00K | 359.00K | 1.20M | 195.00K | 2.05M | 2.69M |
| Total Debt | 20.00K | 20.00K | 43.00K | 75.00K | 69.00K | 230.00K |
| Total Liabilities | 654.00K | 654.00K | 627.00K | 939.00K | 1.23M | 1.08M |
| Stockholders Equity | 669.00K | 669.00K | 1.79M | 1.12M | 3.68M | 4.75M |
Cash Flow | ||||||
| Free Cash Flow | -1.37M | -1.37M | -1.77M | -1.87M | -591.00K | -1.52M |
| Operating Cash Flow | -1.36M | -1.36M | -1.77M | -1.75M | -333.00K | -1.15M |
| Investing Cash Flow | -5.00K | -5.00K | 1.00K | -114.00K | -258.00K | -365.00K |
| Financing Cash Flow | 531.00K | 529.00K | 2.77M | 7.00K | -46.00K | 2.67M |
Fusion Antibodies Plc Technical Analysis
Fusion Antibodies Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | £10.43M | -4.83 | -13.85% | ― | 7.27% | 39.64% | |
| ― | £24.27M | ― | -213.66% | ― | 39.88% | 81.33% | |
| ― | £14.49M | ― | -139.16% | ― | 72.98% | 55.36% | |
| ― | £6.36M | -0.11 | -333.59% | ― | 45.22% | 55.71% | |
| ― | £935.87K | -0.17 | ― | ― | 418.49% | 27.86% |
Fusion Antibodies Plc Corporate Events
Fusion Antibodies plc announced that all resolutions were passed at its recent annual general meeting. This development underscores the company’s stable governance and continued focus on advancing its strategic goals in the rapidly growing monoclonal antibody therapeutics market, which is projected to surpass $445 billion by 2028.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £16.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc reported a decrease in unaudited revenues for the first half of the financial year 2026 compared to the previous year, but an increase from the second half of 2025, with improved gross margins reflecting operational efficiency. The company achieved a significant milestone with a US patent for its OptiMAL® library design and continued its collaboration with the National Cancer Institute, which plans to use the platform for future projects. Fusion secured new contracts, including a stable cell line development for a US biotechnology company and multiple humanization projects, strengthening its industry position. The company anticipates a stronger performance in the second half of the year, supported by a robust order book and promising sales opportunities, and is on track with strategic goals, including the launch of OptiMAL® in December.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £16.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc has secured a new multi-target Integrated Therapeutic Antibody Services project with a European-based global pharmaceutical company. This project, which involves humanizing VHH antibody fragments, underscores Fusion’s strategic focus on partnering with major pharmaceutical firms to drive sustainable growth and enhance market positioning. The project is expected to be completed within the current financial year, generating revenues of at least £175,000, and highlights Fusion’s capability to deliver high-quality, innovative solutions.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £16.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Fusion Antibodies plc announced the posting of its Annual Report and Accounts for the year ended 31 March 2025, along with the Notice of its Annual General Meeting (AGM) scheduled for 16 October 2025. The company continues to focus on enhancing its industry positioning by leveraging technological advances to expedite drug development, which could have significant implications for stakeholders by potentially speeding up the delivery of new therapeutic and diagnostic solutions.
Fusion Antibodies plc has announced significant progress in its OptiMAL® project, a collaboration with the National Cancer Institute (NCI) to develop antibodies for cancer therapy and diagnostics. The NCI has expressed interest in extending the use of the OptiMAL® platform, which has successfully identified antibodies with commercially viable binding affinities. This development enhances Fusion’s industry positioning as a leader in pre-clinical antibody discovery and may have positive implications for stakeholders by potentially accelerating therapeutic and diagnostic projects targeting various cancers.
Fusion Antibodies plc announced an upcoming in-person investor presentation in Belfast on September 18, 2025. This event is part of the company’s strategy to engage with investors and showcase its advancements in antibody engineering services. The presentation reflects Fusion’s commitment to leveraging cutting-edge science to enhance its market position and support the global healthcare industry by expediting the drug development process.
Fusion Antibodies plc reported significant growth in its financial results for the year ending March 2025, with revenues increasing to £1.97 million from £1.14 million the previous year. The company highlighted its strategic progress in the diagnostics market, reducing reliance on the volatile biotech sector, and announced several large contract wins. The successful £1.17 million fundraising and collaboration with the National Cancer Institute have bolstered its flagship OptiMAL® program, positioning the company for further growth. Despite uncertain economic conditions, Fusion Antibodies sees potential opportunities in the biotechnology sector’s funding challenges, as companies may outsource development work to manage costs.
Fusion Antibodies plc announced a new contract win for a humanisation project with a US-based division of a global pharmaceutical company. This project, expected to generate modest revenues, is significant as it highlights Fusion’s ability to secure contracts with large pharmaceutical companies, reducing reliance on smaller clients and showcasing its novel technologies. The project is anticipated to be completed within the current financial year, reinforcing Fusion’s reputation for delivering high-quality therapeutic antibodies and expertise in a competitive market.
Fusion Antibodies plc has secured three follow-on contracts with a US-based biotechnology client, building on their successful Cell Line Development project. These new contracts, valued at approximately $460,000, are expected to significantly contribute to the company’s financial performance for the year ending March 2026. This development underscores Fusion’s strong reputation in delivering high-quality therapeutic antibodies and highlights the company’s growth potential in the pre-clinical antibody discovery and engineering sector.
Fusion Antibodies plc announced plans to host investor presentations in London and Belfast in September and October 2025, alongside participation in the Proactive One2One Investor Forum. The company will also release its financial results for the year ending March 2025 in September. These events aim to engage investors and provide updates on the company’s performance and strategic direction, potentially impacting its market positioning and stakeholder relations.
Fusion Antibodies plc has been granted a U.S. patent for its OptiMAL® antibody library platform, marking a significant milestone in its pre-clinical antibody discovery and engineering services. This patent secures the company’s unique approach to antibody library design and supports its plans for a commercial launch at the Antibody Engineering and Therapeutics conference in San Diego in December 2025, potentially enhancing its market positioning and stakeholder value.